Reconceptualizing the clinicopathological features, locoregional therapy and prognostic factors of occult breast cancer in the era of molecular subtyping

References

• Baron, P. L., M. P. Moore, D. W. Kinne, F. C. Candela, M. P. Osborne, and J. A. Petrek. 1990. Occult breast cancer presenting with axillary metastases. Updated management. Archives of Surgery 125 (2):210–14. doi:10.1001/archsurg.1990.01410140088014.
   PubMedGoogle Scholar
• Becker, S. O., and A. Ichino. 2002. Estimation of average treatment effects based on propensity scores. The Stata Journal 2 (4):358–77. doi:10.1177/1536867X0200200403.
   Web of Science ®Google Scholar
• de Bresser, J., B. de Vos, F. van der Ent, and K. Hulsewe. 2010. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: A systematic review. European Journal of Surgical Oncology (EJSO) 36 (2):114–19. doi:10.1016/j.ejso.2009.09.007.
   PubMed Web of Science ®Google Scholar
• Dehejia, R. H., and S. Wahba. 2002. Propensity score matching methods for non-experimental causal studies. The Review of Economics and Statistics 84 (1):151–61. doi:10.1162/003465302317331982.
   Web of Science ®Google Scholar
• Duggan, M. A., W. F. Anderson, S. Altekruse, L. Penberthy, and M. E. Sherman. 2016. The Surveillance, Epidemiology, and End Results (SEER) program and pathology: Toward strengthening the critical relationship. The American Journal of Surgical Pathology 40 (12):e94–102. doi:10.1097/PAS.0000000000000749.
   PubMed Web of Science ®Google Scholar
• Fragomeni, S. M., A. Sciallis, and J. S. Jeruss. 2018. Molecular subtypes and local-regional control of breast cancer. Surgical Oncology Clinics of North America 27 (1):95–120. doi:10.1016/j.soc.2017.08.005.
   PubMed Web of Science ®Google Scholar
• Ge, L. P., X. Y. Liu, Y. Xiao, Z. C. Gou, S. Zhao, Y. Z. Jiang, and G. H. Di. 2018. Clinicopathological characteristics and treatment outcomes of occult breast cancer: A SEER population-based study. Cancer Management and Research 10:4381–91. doi:10.2147/CMAR.S169019.
   PubMed Web of Science ®Google Scholar
• Giuliano, A. E., K. V. Ballman, L. McCall, P. D. Beitsch, M. B. Brennan, P. R. Kelemen, D. W. Ollila, N. M. Hansen, P. W. Whitworth, P. W. Blumencranz, et al. 2017. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (alliance) randomized clinical trial. JAMA 318 (10):918–26. doi:10.1001/jama.2017.11470.
   PubMed Web of Science ®Google Scholar
• He, M., L. C. Tang, K. D. Yu, A. Y. Cao, Z. Z. Shen, Z. M. Shao, and G. H. Di. 2012. Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer. European Journal of Surgical Oncology (EJSO) 38 (11):1022–28. doi:10.1016/j.ejso.2012.08.022.
   PubMed Web of Science ®Google Scholar
• Hessler, L. K., J. K. Molitoris, P. Y. Rosenblatt, E. C. Bellavance, E. M. Nichols, K. H. R. Tkaczuk, S. J. Feigenberg, S. M. Bentzen, and S. B. Kesmodel. 2017. Factors influencing management and outcome in patients with occult breast cancer with axillary lymph node involvement: Analysis of the National cancer database. Annals of Surgical Oncology 24 (10):2907–14. doi:10.1245/s10434-017-5928-x.
   PubMed Web of Science ®Google Scholar
• Huang, K. Y., J. Zhang, W. F. Fu, Y. X. Lin, and C. G. Song. 2020. Different clinicopathological characteristics and prognostic factors for occult and non-occult breast cancer: Analysis of the SEER database. Frontiers in Oncology 10:1420. doi:10.3389/fonc.2020.01420.
   PubMed Web of Science ®Google Scholar
• Kim, B. H., J. Kwon, and K. Kim. 2018. Evaluation of the benefit of radiotherapy in patients with occult breast cancer: A population-based analysis of the SEER database. Cancer Research and Treatment 50 (2):551–61. doi:10.4143/crt.2017.189.
   PubMed Web of Science ®Google Scholar
• Kinoe, H., K. Yamanouchi, S. Kuba, M. Morita, C. Sakimura, M. Kanetaka, K. Abe, K. Takatsuki, N. Hayashida, and S. Eguchi. 2018. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis. Journal of the American College of Surgeons 23 (4):60–66. doi:10.1016/j.jamcollsurg.2018.08.012.
   Web of Science ®Google Scholar
• Macedo, F. I., J. J. Eid, J. Flynn, M. J. Jacobs, and V. K. Mittal. 2016. Optimal surgical management for occult breast carcinoma: A meta-analysis. Annals of Surgical Oncology 23 (6):1838–44. doi:10.1245/s10434-016-5104-8.
   PubMed Web of Science ®Google Scholar
• Montagna, E., V. Bagnardi, N. Rotmensz, G. Viale, G. Cancello, M. Mazza, A. Cardillo, R. Ghisini, V. Galimberti, P. Veronesi, et al. 2011. Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation. Breast Cancer Research and Treatment 129 (3):867–75. doi:10.1007/s10549-011-1697-6.
   PubMed Web of Science ®Google Scholar
• Patel, J., T. Nemoto, D. Rosner, T. L. Dao, and J. W. Pickren. 1981. Axillary lymph node metastasis from an occult breast cancer. Cancer 47 (12):2923–27. doi:10.1002/1097-0142(19810615)47:12<2923:AID-CNCR2820471231>3.0.CO;2-N.
   PubMed Web of Science ®Google Scholar
• Pentheroudakis, G., G. Lazaridis, and N. Pavlidis. 2010. Axillary nodal metastases from carcinoma of unknown primary (CUPAx): A systematic review of published evidence. Breast Cancer Research and Treatment 119 (1):1–11. doi:10.1007/s10549-009-0554-3.
   PubMed Web of Science ®Google Scholar
• Ping, S., W. H. Ming, S. H. Bin, W. D. Wen, Q. Cheng, C. C. Jun, H. Y. Bin, and C. Z. Jian. 2014. Comparison of clinical characteristics between occult and non-occult breast cancer. J BUON 19 (3):662–66.
   PubMed Web of Science ®Google Scholar
• Rosen, P. P. 1980. Axillary lymph node metastases in patients with occult noninvasive breast carcinoma. Cancer 46:1298–306. doi:10.1002/1097-0142/19800901/46:5<1298:aid-cncr2820460535>3.0.co;2-2.
   PubMed Web of Science ®Google Scholar
• Rosen, P. P., and M. Kimmel. 1990. Occult breast carcinoma presenting with axillary lymph node metastases: A follow-up study of 48 patients. Human Pathology 21 (5):518–23. doi:10.1016/0046-8177(90)90008-s.
   PubMed Web of Science ®Google Scholar
• Sohn, G., B. H. Son, S. J. Lee, E. Y. Kang, S. H. Jung, S. H. Cho, S. Baek, Y. R. Lee, H. J. Kim, B. S. Ko, et al. 2014. Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: A nationwide retrospective study. Journal of Surgical Oncology 110 (3):270–74. doi:10.1002/jso.23644.
   PubMed Web of Science ®Google Scholar
• Walker, G. V., G. L. Smith, G. H. Perkins, J. L. Oh, W. Woodward, T. K. Yu, K. K. Hunt, K. Hoffman, E. A. Strom, and T. A. Buchholz. 2010. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer 116 (17):4000–06. doi:10.1002/cncr.25197.
   PubMed Web of Science ®Google Scholar
• Wang, J., Y. F. Zhang, X. Wang, J. Wang, X. Yang, Y. Q. Gao, and Y. Fang. 2013. Treatment outcomes of occult breast carcinoma and prognostic analyses. Chinese Medical Journal 126 (16):3026–29.
   PubMed Web of Science ®Google Scholar
• Wu, S. G., W. W. Zhang, J. Y. Sun, F. Y. Li, H. X. Lin, Y. X. Chen, and Z. Y. He. 2017. Comparable survival between additional radiotherapy and local surgery in occult breast cancer after axillary lymph node dissection: A population-based analysis. Journal of Cancer 8 (18):3849–55. doi:10.7150/jca.21217.
   PubMed Web of Science ®Google Scholar